Literature DB >> 27059361

Health Impact of Rotavirus Vaccination in Developing Countries: Progress and Way Forward.

Umesh D Parashar1, Hope Johnson2, A Duncan Steele3, Jacqueline E Tate1.   

Abstract

Two rotavirus vaccines have been licensed in >100 countries worldwide since 2006. As of October 2105, these vaccines have been implemented in the national immunization programs of 79 countries, including 36 low-income countries that are eligible for support for vaccine purchase from Gavi, the Vaccine Alliance. Rotavirus vaccines were initially introduced in Australia and countries of the Americas and Europe after completion of successful clinical trials in these regions, and the impact of routine vaccination in reducing the health burden of severe childhood gastroenteritis in these regions has been well documented. Because of concerns around the performance of orally administered rotavirus vaccines in developing countries, vaccine implementation in these settings only began after additional clinical trials were completed and the World Health Organization issued a global recommendation for use of rotavirus vaccines in 2009. This supplementary issue of Clinical Infectious Diseases includes a collection of articles describing the impact and effectiveness of routine rotavirus vaccination in developing countries that were among the early adopters of rotavirus vaccine. The data highlight the benefits of vaccination and should provide valuable evidence to sustain vaccine use in these countries and encourage other countries to adopt routine rotavirus vaccination to reduce the health burden of severe childhood gastroenteritis.
© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.

Entities:  

Keywords:  developing countries; effectiveness; impact; rotavirus; rotavirus vaccines

Mesh:

Substances:

Year:  2016        PMID: 27059361     DOI: 10.1093/cid/civ1015

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  35 in total

1.  Evaluation of the Influence of Gastrointestinal Coinfections on Rotavirus Vaccine Effectiveness in Botswana.

Authors:  Margaret Mokomane; Jacqueline E Tate; Andrew P Steenhoff; Mathew D Esona; Michael D Bowen; Kwana Lechiile; Jeffrey M Pernica; Ishmael Kasvosve; Umesh D Parashar; David M Goldfarb
Journal:  Pediatr Infect Dis J       Date:  2018-03       Impact factor: 2.129

2.  Evolution of P[8], P[4], and P[6] VP8* genes of human rotaviruses globally reported during 1974 and 2017: possible implications for rotavirus vaccines in development.

Authors:  Daniel E Velasquez; Baoming Jiang
Journal:  Hum Vaccin Immunother       Date:  2019-06-13       Impact factor: 3.452

3.  Incidence and epidemiology of intussusception among children under 2 years of age in Chenzhou and Kaifeng, China, 2009-2013.

Authors:  Na Liu; Catherine Yen; Tao Huang; Pengwei Cui; Jacqueline E Tate; Baoming Jiang; Umesh D Parashar; Zhao-Jun Duan
Journal:  Vaccine       Date:  2018-02-10       Impact factor: 3.641

Review 4.  A Meta-analysis Assessing Diarrhea and Pneumonia in HIV-Exposed Uninfected Compared With HIV-Unexposed Uninfected Infants and Children.

Authors:  Alana T Brennan; Rachael Bonawitz; Christopher J Gill; Donald M Thea; Mary Kleinman; Lawrence Long; Caitryn McCallum; Matthew P Fox
Journal:  J Acquir Immune Defic Syndr       Date:  2019-09-01       Impact factor: 3.731

5.  One-step Quantitative RT-PCR Assays for Detecting, Genotyping and Differentiating Wild-Type Group a Rotaviruses and Vaccine (Rotarix® and RotaTeq®) Strains in Stool Samples.

Authors:  Rashi Gautam; Michael D Bowen
Journal:  J Vaccines Vaccin       Date:  2016-09-26

6.  Whole-genome sequencing and analyses identify high genetic heterogeneity, diversity and endemicity of rotavirus genotype P[6] strains circulating in Africa.

Authors:  Martin M Nyaga; Yi Tan; Mapaseka L Seheri; Rebecca A Halpin; Asmik Akopov; Karla M Stucker; Nadia B Fedorova; Susmita Shrivastava; A Duncan Steele; Jason M Mwenda; Brett E Pickett; Suman R Das; M Jeffrey Mphahlele
Journal:  Infect Genet Evol       Date:  2018-05-18       Impact factor: 3.342

7.  Formulation development of a live attenuated human rotavirus (RV3-BB) vaccine candidate for use in low- and middle-income countries.

Authors:  Prashant Kumar; Ravi S Shukla; Ashaben Patel; Swathi R Pullagurla; Christopher Bird; Oluwadara Ogun; Ozan S Kumru; Ahd Hamidi; Femke Hoeksema; Christopher Yallop; Julie E Bines; Sangeeta B Joshi; David B Volkin
Journal:  Hum Vaccin Immunother       Date:  2021-04-16       Impact factor: 3.452

8.  Wa-1 Equine-Like G3P[8] Rotavirus from a Child with Diarrhea in Colombia.

Authors:  Marlen Martinez-Gutierrez; Estiven Hernandez-Mira; Santiago Rendon-Marin; Julian Ruiz-Saenz
Journal:  Viruses       Date:  2021-06-04       Impact factor: 5.048

9.  Identifying signatures of the impact of rotavirus vaccines on hospitalizations using sentinel surveillance data from Latin American countries.

Authors:  Kayoko Shioda; Lucia Helena de Oliveira; Jennifer Sanwogou; Gloria Rey-Benito; Diana Nuñez Azzad; Roxana Elizabeth Castillo; María Liz Gamarra Ramírez; Marta Raquel Von Horoch; Daniel M Weinberger; Virginia E Pitzer
Journal:  Vaccine       Date:  2019-10-28       Impact factor: 4.169

10.  Using surveillance and economic data to make informed decisions about rotavirus vaccine introduction.

Authors:  Adam L Cohen; Negar Aliabadi; Fatima Serhan; Jacqueline E Tate; Patrick Zuber; Umesh D Parashar
Journal:  Vaccine       Date:  2018-08-18       Impact factor: 4.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.